Serum potassium levels provide prognostic information in symptomatic heart failure beyond traditional clinical variables

Camila Cristiane Toledo¹, Pedro Vellosa Schwartzmann³, Luis Miguel Silva¹, Gabriel da Silva Ferreira¹, Fernando Bianchini Cardoso¹, Vinicius Citelli Ribeiro¹, Layde Rosane Paim¹, Lígia M. Antunes-Correa¹,², Andrei Carvalho Sposito¹, Jose Roberto Matos Souza¹, Rodrigo Modolo¹, Wilson Nadruz³, Luis Sergio Fernandes de Carvalho¹ and Otávio R. Coelho-Filho¹*

¹Faculty of Medical Science, University of Campinas, São Paulo, Brazil; ²School of Physical Education, University of Campinas, São Paulo, Brazil; and ³Cardiology Unit, Unimed Hospital, Ribeirão Preto, São Paulo, Brazil

Abstract

Aims Despite of recent advances in the pharmacological treatment, heart failure (HF) maintains significant morbidity and mortality rates. While serum potassium disorders are common and associated with adverse outcomes, the exact recommended potassium level for patients with HF are not entirely established. We aimed to investigate the prognostic role of potassium levels on a cohort of patients with symptomatic chronic HF.

Methods and results Patients with symptomatic chronic HF were identified at the referral to 6 min walking test (6MWT) and were prospectively followed up for cardiovascular events. Clinical and laboratorial data were retrospectively obtained. The primary endpoint was the composite of cardiovascular death, hospitalization due to HF, and heart transplantation. The cohort included 178 patients with HF with the mean age of 51 ± 12.76 years, 39% were female, 85% of non-ischaemic cardiomyopathy, and 38% had New York Heart Association Class III with a relatively high Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score (12.91 ± 6.6). The mean left ventricular ejection fraction was 39.98 ± 15.79%, and the mean 6MWT distance was 353 ± 136 m. After a median follow-up of 516 days, there were 22 major cardiovascular events (4 cardiovascular deaths, 13 HF admissions, and 5 heart transplants). Patients were stratified according to cut-point level of serum potassium of 4.7 mmol/L to predict combined cardiac events based on receiver operating characteristic analysis. Individuals with higher potassium levels had worse renal function (glomerular filtration rate, K ≤ 4.7: 102.8 ± 32.2 mL/min/1.73 m² vs. K > 4.7: 85.42 ± 36.2 mL/min/1.73 m², P = 0.004), higher proportion of New York Heart Association Class III patients (K ≤ 4.7: 28% vs. K > 4.7: 48%, P = 0.0029), and also higher MAGGIC score (K ≤ 4.7: 12.08 ± 5.7 vs. K > 4.7: 14.9 ± 7.9, P = 0.0089), without significant differences on the baseline pharmacological HF treatment. Both potassium levels [hazard ratio (HR) 4.26, 95% confidence interval (CI) 1.59–11.421, P = 0.003] and 6MWT distance (HR 0.99, 95% CI 0.993–0.999, P = 0.01) were independently associated with the primary outcome. After adjustments for MAGGIC score and 6MWT distance, potassium levels > 4.7 mmol/L maintained a significant association with outcomes (HR 3.57, 95% CI 1.305–9.807, P = 0.013). Patients with K > 4.7 mmol/L were more likely to present clinical events during the follow-up (log rank = 0.005). Adding potassium levels to the model including 6MWT and MAGGIC significantly improved the prediction of events over 2 years (integrated discrimination index 0.105, 95% CI 0.018–0.281, P = 0.012 and net reclassification index 0.447, 95% CI 0.077–0.703, P = 0.028).

Conclusions Potassium levels were independently associated with worse outcomes in patients with chronic symptomatic HF, also improving the accuracy model for prognostic prediction when added to MAGGIC score and 6MWT distance. The potassium levels above 4.7 mmol/L might identify those patients at an increased risk of cardiovascular events.

Keywords Heart failure; Prognosis; Potassium; Renal function; Physical capacity

Received: 10 December 2020; Revised: 27 January 2021; Accepted: 20 February 2021

*Correspondence to: Otávio Rizzi Coelho-Filho, MD, MPH, PhD, Assistant Professor of Medicine, Division of Cardiology, Department of Medicine, State University of Campinas (UNICAMP), Rua Tessália Viera de Camargo, 126 Campinas, São Paulo CEP 13083-887, Brazil. Tel: +55 19 996038484; Fax: +55 19 35218788; Twitter: @Otavio_Coelho_F. Email: orcfilho@unicamp.br

© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Introduction

Heart failure (HF) is a common clinical syndrome characterized by a reduction in cardiac output and/or increase in intracardiac pressures at rest or during exercise, which is strongly associated to reduced functional capacity, poor quality of life, and cardiac events including cardiovascular death and hospitalization rates. In the USA, more than 550,000 patients are diagnosed with HF yearly, and, in Brazil, HF represents one of the most frequent causes of cardiovascular hospitalization in the elderly population. Despite having a high prevalence and newer pharmacological treatment advances, HF still maintains high morbidity and mortality rates.

In the HF population, serum potassium disorders (hyperkalaemia and hypokalaemia) are common and frequently associated with adverse outcomes. Diabetes, chronic kidney disease, and hypertension are frequent co-morbidities in individuals with HF, playing a significant role in the potassium disturbances. Hyperkalaemia is markedly related to poor outcomes in patients with HF and often leads to an increased risk of life-threatening arrhythmias and to discontinuation or reduction of the renin–angiotensin–aldosterone system (RAAS) inhibitors, which may impact survival. Likewise, hypokalaemia might also be present among patients with HF, despite the use of RAAS inhibitors. In a recent study, a U-shaped relation between potassium and mortality in patients with acute HF was reported. Whether potassium is an independent risk factor for worse outcomes or related to other risk factors such as chronic kidney disease or diabetes remains unclear, although hyperkalaemia has been consistently linked to mortality increase.

With a growing number of patients with HF with associated multiple co-morbidities receiving RAAS inhibitors and also mineralocorticoid receptor antagonists, hyperkalaemia has become a common condition that impairs the initiation and up-titration of life-saving HF therapies.

Noteworthy, the ideal potassium levels that should be maintained in patients with HF have not been well established. Moreover, the impact of potassium levels in ambulatory real-world HF patients has yet to be further investigated. In this study, we aimed to assess the impact of potassium levels on the prognosis of an ambulatory chronic and symptomatic HF cohort.

Methods

Study population

Patients with symptomatic chronic HF followed at the outpatient HF clinic of a tertiary hospital (Discipline of Cardiology, Clinics Hospital, Faculty of Medical Science, University of Campinas, São Paulo, Brazil) referred for 6 min walking test (6MWT) were consecutively identified. The eligibility criteria included patients with symptomatic HF (Stage C HF with a New York Heart Association (NYHA) Class II or III) at age between 18 and 75 years receiving optimized guideline-based HF therapy. The exclusion criteria were advanced or decompensated HF, significant cardiac valve disease other than functional mitral or tricuspid regurgitation, significant asthma or chronic obstructive pulmonary disease, pregnancy, unstable clinical condition, unavailability of follow-up, and inability to perform a 6MWT.

Study design

Patients underwent a baseline evaluation, after the 6MWT, and were prospectively followed for cardiovascular events. The baseline evaluation included clinical and a single laboratorial evaluation based on the available data and tests obtained in medical records matched to the 6WMT. Left ventricular ejection fraction (LVEF) by transthoracic echocardiogram (Simpson method’s) assessment and a 6MWT were available in all recruited patients. After the initial evaluation, patients were followed for major cardiovascular events (cardiac death, HF hospitalization, and heart transplantation) in a specialized HF outpatient clinic in accordance with the most recent guidelines. Cardiac death was defined as any sudden death occurred preceding cardiovascular symptoms (syncope, chest pains, or dyspnoea). HF hospitalization was defined as any hospital admission triggered by clinically decompensated HF requiring intravenous loop diuretics for more than 24 h. Cardiac events (cardiac death, HF hospitalization, and heart transplantation) were obtained based on the available medical documentation of our hospital and health care network, blinded to any clinical information. The study was conducted according to the precepts of the Helsinki Declaration and was approved by the research ethics committee of our institution (CAAE: 39500514.2.0000.5404). All patients provided consent to participate.

Echocardiogram

Cardiac ultrasound analysis was performed using a dedicated phased array transducer (1.5–4.5 MHz, Vivid-S60, GE Healthcare, Chicago, USA). Cardiac chambers and LVEF evaluation (assessed by the Simpson’s method) were performed according to the current American Society of Echocardiography guidelines. Left ventricular relative wall thickness (RWT) was estimated as 2*posterior wall thickness/end-diastolic diameter.
Six-minute walking test

The 6MWT was performed as previously described on a surface level by a health care professional unaware of clinical, laboratorial, or echocardiographic results. Each patient underwent two 6MWTs performed at the same day, with the first test performed in order to familiarize the patient with the methodology. The second test was performed with a maximal performance with instructions to cover the greatest distance during the test time, at a self-determined speed, and the patients were allowed to pause and rest if needed. Two different health care professionals objectively measured the distance covered.

Laboratory and electrocardiogram data

Twelve-lead resting electrocardiogram (ECG) was obtained through calibrated and validated equipment. Standard definitions for chamber enlargement were considered as left atrial enlargement (second deflection of P wave on V1 > 1 mm), left ventricular enlargement (any of SV1 + RV5 or V6 > 35 mm or R1 + SII > 25 mm), right atrial enlargement (initial component of P wave on II taller than 2.5 mm), and right ventricular enlargement (any of R/S V1 > 1 or RV1 > 5 mm or SV5 or V6 > 7 mm). Glucose, haemoglobin, sodium, potassium, urea, creatinine, triglycerides, and high-density and low-density lipoprotein cholesterol were obtained by standard methods (Beckman Coulter, AU5800 Beckman Coulter Analyzer, USA). Twelve-hour fasting was performed for glucose and lipids.

Statistical methods

Data are reported as mean ± standard deviation. All statistical analyses were performed using SAS Version 9.4 (SAS Institute, Inc., Cary, NC) and SPSS (IBM Corp, IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY). The Kolmogorov–Smirnov test was used to test whether the variables showed normal distribution. For comparison of the variable mean values, we used the Student’s t-test. Fisher’s exact test was used to test the association between the nominal variables. Clinical predictors were transformed when appropriate. Receiver operating characteristic analysis was used to obtain the ideal cut-point level of serum potassium to predict combined cardiac events. Survival analysis was performed using Kaplan–Meier curves, log-rank test, and Cox regression analysis. The Meta-Analysis Global Group in Chronic Heart Failure score (MAGGIC score), 6MWT distance, and potassium levels were included in the multivariable model. Harrell’s C-statistics was used to verify discrimination of risk prediction models. Continuous net reclassification index (NRI) and integrated discrimination index (IDI) were calculated as previously described. The level of significance was set at P < 0.05 in all analyses.

Results

Baseline evaluation and population characteristics

The demographic, clinical characteristics and echocardiogram parameters of the study population at the baseline evaluation are summarized in Tables 1 and 2. The cohort included 178 patients with HF. The mean age was 51 ± 12.76 years, 39% were female, 85% of non-ischaemic cardiomyopathy, and 38% had NYHA Class III with a relatively high MAGGIC score of 12.91 ± 6.6. The mean LVEF was 39.98 ± 15.79% through Simpson’s measurement, with a high mean left ventricular internal dimension in diastole (64.46 ± 11.47 mm) and an RWT of 0.31 ± 0.09. While our cohort included predominantly patients with HF with reduced ejection fraction, 31% of our patients had an LVEF > 45% (n = 55) and 69% had an LVEF ≤ 45% (n = 123). Regarding the 6MWT, the mean achieved distance was 353 ± 136 m. Patients were well treated for HF in accordance with the most recent guidelines with 89% and 88% of beta-blocker and RAAS inhibitors, respectively.

Mean potassium level of the entire cohort was 4.6 ± 0.32 mmol/L, and the majority of patients (70.7%) had potassium levels within the normal range (Table 2). Patients with higher potassium levels were older and more symptomatic, as confirmed by higher NYHA class, had a higher MAGGIC score, and had a more advanced renal dysfunction (Table 1).

Patients were stratified by potassium levels below (126 patients) and above 4.7 mmol/L (52 patients) according to the receiver operating characteristic analysis for better accuracy, which showed that the potassium level of 4.7 mmol/L had the best area under the curve (Figure 2) to predict cardiovascular events. When considering the subgroups of potassium levels below and above 4.7 mmol/L, there were no significant differences on HF therapies, even when including the RAAS blockade with mineralocorticoid antagonists. Patients with K ≤ 4.7 mmol/L exhibited a higher percentage of patients under diuretic therapy and calcium channel blockers (Table 1). Additionally, patients with K > 4.7 mmol/L demonstrated higher MAGGIC score, worse NYHA class, and more tobacco use — the subgroups characteristics and comparisons are displayed in Tables 1 and 2. There were no significant differences on 6MWT exercise parameters between the subgroups.

Moreover, in patients with higher potassium levels, the glomerular filtration rate was lower (patients with K ≤ 4.7 mmol/L presented 102.8 ± 32.2 mL/min/1.73 m² vs.
85.42 ± 36.2 mL/min/1.73 m² in patients with K > 4.7 mmol/L, P < 0.001), without any significant differences on other laboratorial analysis. Nevertheless, there were no differences on 12-lead resting ECG parameters, with similar rates of atrial fibrillation, chambers’ enlargement, or QRS duration. The main difference on echocardiographic parameters between the groups was the lower RWT in patients with higher potassium levels (K ≤ 4.7 mmol/L presented 0.32 ± 0.09 vs. 0.29 ± 0.08 in the K > 4.7 mmol/L group, P < 0.0001). It is important to highlight that both groups were also receiving similar modifiable HF therapies.

Univariate analyses for adverse outcomes

After a median follow-up period of 516 days (ranging from 39 to 1340 days), there were 22 major cardiovascular events, including 4 cardiovascular deaths, 13 HF admissions, and 5 heart transplants.

Survival by Kaplan–Meier and event rates analysis

Patients with potassium levels > 4.7 mmol/L had a significantly higher likelihood to experience adverse outcomes during the follow-up as compared with patients with
### Table 2: Six-minute walking test exercise parameters, laboratorial analysis, and electrocardiogram and echocardiogram characteristics of the study population stratified by levels of potassium (> or ≤4.7 mmol/L)

|                               | All patients (N = 178) | Patients with K ≤ 4.7 (N = 126) | Patients with K > 4.7 (N = 52) | P-value  |
|-------------------------------|------------------------|----------------------------------|--------------------------------|---------|
| **Haemodynamics physical capacity** |                        |                                  |                                |         |
| Systolic blood pressure (resting), mmHg | 119.2 ± 23.53          | 120.1 ± 23.89                    | 117.1 ± 22.69                  | 0.4494  |
| Diastolic blood pressure (resting), mmHg | 76.2 ± 13.6            | 76.8 ± 13.7                      | 74.5 ± 13.4                    | 0.3096  |
| Systolic blood pressure (after 6MWT), mmHg | 123.2 ± 27.7           | 125.5 ± 29.1                     | 117.8 ± 23.6                   | 0.0986  |
| Diastolic blood pressure (after 6MWT), mmHg | 77.2 ± 14.5            | 78.4 ± 14.9                      | 74.3 ± 13.2                    | 0.0928  |
| Heart rate, b.p.m.           | 73.8 ± 14.9            | 74.5 ± 13.9                      | 72.4 ± 17.1                    | 0.4013  |
| Distance in the 6 min walk test, m | 353.0 ± 136            | 360.8 ± 137                      | 334.0 ± 132.8                  | 0.2330  |
| **Laboratory analyses**       |                        |                                  |                                |         |
| Haemoglobin, g/dL            | 13.6 ± 1.82            | 13.6 ± 1.7                       | 13.7 ± 1.8                     | 0.8433  |
| Sodium, mmol/L              | 138.1 ± 2.8            | 137.9 ± 3.8                      | 137.0 ± 4.0                    | 0.178   |
| Potassium, mmol/L           | 4.6 ± 0.32             | 4.32 ± 0.29                      | 5.08 ± 0.34                    | <0.001  |
| Creatinine, mg/dL           | 1.1 ± 0.2              | 1.03 ± 0.4                       | 1.34 ± 0.9                     | 0.0036  |
| Glomerular filtration rate, mL/min/1.73 m² | 97.62 ± 34.2            | 102.8 ± 32.2                     | 85.42 ± 36.2                   | 0.0040  |
| Urea, mg/dL                 | 42.5 ± 14.4            | 37.4 ± 13.3                      | 53.1 ± 32.4                    | <0.0001 |
| Total cholesterol, mg/dL     | 159.6 ± 39.3           | 159.4 ± 40.5                     | 165 ± 45.5                     | 0.4462  |
| Triglycerides, mg/dL         | 130.7 ± 77.4           | 154.3 ± 130.6                    | 144 ± 99.4                     | 0.6363  |
| LDL-cholesterol, mg/dL       | 86.3 ± 34.6            | 89.26 ± 34.7                     | 90.40 ± 35.5                   | 0.8574  |
| HDL-cholesterol, mg/dL       | 41.5 ± 5.3             | 40.24 ± 10.2                     | 35.62 ± 6.1                    | 0.2410  |
| Glucose, mg/dL              | 110.4 ± 45.9           | 108.1 ± 48.5                     | 120.3 ± 78.2                   | 0.2437  |
| **Resting 12-lead electrocardiogram** |                      |                                  |                                |         |
| Atrial fibrillation, % (N)   | 8% (15)                | 13% (11)                         | 11% (4)                        | 0.99    |
| QRS duration, ms            | 119.1 ± 37.12          | 116.4 ± 36.62                    | 125.3 ± 38.05                  | 0.233   |
| QTc, ms                     | 404.2 ± 60.1           | 401.7 ± 64.6                     | 410.3 ± 47.8                   | 0.4783  |
| Left bundle branch block     | 38% (68)               | 56% (47)                         | 58% (21)                       | 0.8432  |
| Right bundle branch block    | 1% (2)                 | 1% (1)                           | 3% (1)                         | 0.5118  |
| Q wave, % (N)               | 1% (1)                 | 1% (1)                           | 0% (0)                         | 0.99    |
| Left atrium enlargement, % (N) | 19% (33)               | 28% (24)                         | 25% (9)                        | 0.8242  |
| Left ventricular hypertrophy, % (N) | 29% (52)               | 45% (37)                         | 42% (15)                       | 0.8418  |
| **Echocardiographic characteristics** |                      |                                  |                                |         |
| Ascending aorta, mm          | 2.73 ± 6.80            | 3.08 ± 7.06                      | 1.80 ± 6.01                    | 0.2772  |
| Aortic root, mm             | 32.15 ± 4.34           | 31.93 ± 4.60                     | 32.68 ± 3.73                   | 0.3987  |
| Left atrium dimension, mm    | 44.70 ± 8.10           | 44.21 ± 8.22                     | 46.02 ± 7.80                   | 0.2712  |
| Left ventricular internal dimensions | 33.96 ± 26.99       | 32.71 ± 26.66                    | 37.02 ± 27.80                  | 0.3372  |
| in systole, mm              | 64.46 ± 11.47          | 62.97 ± 11.19                    | 67.01 ± 12.64                  | 0.0857  |
| Left ventricular internal dimensions in diastole, mm | | | | |
| Septal wall dimension, mm    | 9.52 ± 2.35            | 9.51 ± 2.28                      | 9.55 ± 2.56                    | 0.9234  |
| Posterior wall dimension, mm | 9.26 ± 2.44            | 9.27 ± 2.48                      | 9.40 ± 2.62                    | 0.8758  |
| Relative wall thickness      | 0.31 ± 0.09            | 0.32 ± 0.09                      | 0.29 ± 0.08                    | 0.0832  |
| Left ventricular ejection fraction, % | 39.98 ± 15.79      | 40.63 ± 16.23                    | 38.33 ± 14.64                  | 0.3896  |

6MWT, 6 min walking test; Hb1Ac, haemoglobin A1c.

Potassium levels ≤ 4.7 mmol/L (Figure 2 demonstrates the Kaplan–Meier analysis stratified by potassium levels and MAGGIC score). Intriguingly, an analysis combining potassium levels and MAGGIC score suggested that potassium levels might offer prognostic information complementary to MAGGIC score (Figure 2C).

Figure 3 shows the annual event rates of adverse outcomes. Higher levels of potassium (K > 4.7 mmol/L) in either group of MAGGIC scores identified patients at a higher risk to experience adverse outcomes. While patients with HF with both high levels of potassium and MAGGIC score had an elevated annualized event rate of 15.9, patients with low levels of both K and MAGGIC had a very low annualized event rate of 1.1, highlighting the possible complementary predictive value of potassium levels in patients with symptomatic HF. Moreover, potassium levels ≤ 4.7 mmol/L along with lower MAGGIC score identified the lowest-risk group (annualized event rate of 1.1) in our cohort, which was significantly lower than the annualized event rate observed in patients with higher potassium and MAGGIC score levels (annualized event rate of 15.9, P < 0.05).

**Multivariable analyses for adverse outcomes**

After adjustments through multivariable analysis for contributing factors such as the MAGGIC score and 6MWT distance, potassium levels presented a significant association with outcomes (HR 3.57, 95% confidence interval CI 1.305–9.807, P = 0.013). MAGGIC score did not maintain a significant outcome prediction in this multivariate analysis (HR 1.09, 95% CI 0.996–1.200, P = 0.06). No other parameter included in the
multivariable model analysis other than K was significantly correlated with outcomes (age, LVEF, or 6MWT distance) (Table 4). Interestingly, both LVEF as a continuous variable and the presence of LVEF > 45% were not associated with cardiac events (HR 0.96, 95% CI 0.931–1.005, \( P = 0.08 \) and HR 0.329, 95% CI 0.075–1.44, \( P = 0.14 \), respectively; Table 3). Additionally, serum potassium maintained its association with cardiovascular events even when adjusting for well-established markers of renal function, such as glomerular filtration rate and creatinine level (Supporting Information, Tables S1 and S2).

We also performed a sensitivity analysis by building a multivariable Cox model including the following categorical variables: 6MWT distance (above or below 300 m), MAGGIC score (above or below 12), and potassium levels (above or below 4.7 mmol/L). Interestingly, MAGGIC score did not show any prognostic value in this analysis (HR 1.68, 95% CI 0.543–5.221, \( P = 0.367 \)). When adding potassium levels above 4.7 mmol/L to the model as a categorical variable, this variable showed a significant association with outcomes (HR 4.109, 95% CI 1.4707–11.4849, \( P = 0.007 \)), as well as 6MWT distance (HR 0.995, 95% CI 0.9918–0.9995, \( P = 0.029 \)) (Table 5).

In order to investigate the incremental value of potassium levels, we compared the predictive power of multivariable models using Harrell’s C-statistics, including MAGGIC score and 6MWT, without and with the addition of potassium levels (Table 6). The addition of serum K provides incremental prediction of cardiovascular events beyond established clinical variables (incremental C-statistic 0.09, \( P = 0.003 \)). Moreover, both IDI and NRI analyses confirmed that the addition of potassium to the model including 6MWT and MAGGIC significantly improved the prediction of cardiovascular events over 2 years (IDI 0.105, 95% CI 0.018–0.281, \( P = 0.012 \) and NRI 0.447, 95% CI 0.077–0.703, \( P = 0.028 \)) (Table 6).

**Discussion**

The main result of the present investigation, performed in a real-world chronic symptomatic HF cohort, was an independent association of potassium levels with combined cardiac adverse events. Moreover, potassium levels significantly improved the predictive value of prognostic models comprising MAGGIC score and 6MWT distance. Also, because serum potassium maintained its association to cardiovascular events after adjusting for renal function, its association with cardiovascular events appeared to be independent of renal function status.

Interestingly, the best accuracy prediction model showed that potassium level of 4.7 mmol/L was the best cut-off value for outcome assessment, which at our best knowledge, is a promising novel-feasible and widely available serum biomarker in symptomatic HF ambulatory population. Despite not having significant hyperkalaemia, which is an established worse prognostic factor, patients with HF in our cohort with potassium levels above 4.7 had higher likelihood to present a worse cardiovascular outcome even when potassium levels were within normal values. This result contrasts
Table 3 Univariable prognostic association with combined cardiac events

|                                | All patients (N = 178) |   |   |
|--------------------------------|------------------------|---|---|
|                                | LR $\chi^2$ test       | HR (95% CI) | P-value |
| **Clinical characteristics**   |                        |   |   |
| Age, per year                  | 0.012                  | 1.00 (0.965–1.041) | 0.91 |
| Female                         | 2.9254                 | 0.34 (0.097–1.172) | 0.09 |
| Height                         | 1.21                   | 1.02 (0.98–1.076)  | 0.27 |
| Weight                         | 0.52                   | 0.99 (0.964–1.017) | 0.46 |
| Body mass index, kg/m$^2$      | 1.17                   | 0.95 (0.89–1.034)  | 0.27 |
| Diabetes                       | 1.62                   | 0.38 (0.087–1.674) | 0.20 |
| History of hypertension        | 0.12                   | 0.83 (0.312–2.254) | 0.72 |
| Hyperlipidaemia                | 0.46                   | 0.67 (0.222–2.071) | 0.49 |
| Obesity                        | 1.33                   | 0.30 (0.04–2.296)  | 0.24 |
| Prior history of stroke        | 2.47                   | 2.78 (0.778–9.94)  | 0.11 |
| Prior history of CABG          | 1.23                   | 3.17 (0.411–24.335) | 0.26 |
| Tobacco use                    | 8.32                   | 4.12 (1.574–10.788) | 0.003 |
| History of alcohol abuse       | 5.53                   | 3.27 (1.22–8.807)  | 0.01 |
| NYHA class                     | 5.122                  | 1.92 (1.092–3.393) | 0.02 |
| MAGGIC score                   | 6.65                   | 1.99 (1.022–1.172) | 0.009 |
| **Laboratory data**            |                        |   |   |
| Sodium, mmol/L                 | 10.94                  | 0.90 (0.847–0.958) | 0.0009 |
| Potassium, mmol/L              | 8.30                   | 4.26 (1.59–11.421) | 0.003 |
| Sodium/potassium               | 9.5                    | 0.77 (0.663–0.913) | 0.002 |
| Potassium binary (≥ or ≤4.7 mmol/L) | 6.98               | 3.67 (1.399–0.9632) | 0.008 |
| Urea, g/dL                     | 13.82                  | 1.02 (1.014–1.044) | 0.0002 |
| Creatinine, mg/dL              | 8.56                   | 1.83 (1.223–2.765) | 0.003 |
| Glomerular filtration rate, mL/min/1.73 m$^2$ | 8.57               | 0.978 (0.963–0.993) | 0.0034 |
| Total cholesterol, mg/dL       | 4.02                   | 0.98 (0.974–1)    | 0.044 |
| LDL-cholesterol, mg/dL         | 0.41                   | 0.99 (0.98–1.01)  | 0.51 |
| HDL-cholesterol, mg/dL         | 0.01                   | 0.046             | 0.99 |
| Triglycerides, mg/dL           | 0.94                   | 0.99 (0.991–1.003) | 0.33 |
| Glucose, mg/dL                 | 2.66                   | 0.98 (0.963–1.004) | 0.10 |
| HbA1c, %                       | 1.54                   | 0.80 (0.568–1.135) | 0.21 |
| Haemoglobin, g/dL              | 1.66                   | 0.83 (0.635–1.098) | 0.19 |
| **6MWT data**                  |                        |   |   |
| Systolic blood pressure (resting), mmHg | 1.44             | 0.98 (0.963–1.009) | 0.22 |
| Diastolic blood pressure (resting), mmHg | 0.04          | 0.99 (0.953–1.024) | 0.50 |
| Heart rate (resting), b.p.m.   | 3.15                   | 0.97 (0.944–1.003) | 0.07 |
| Heart rate (after 6MWT), b.p.m. | 0.36                   | 0.97 (0.971–1.016) | 0.54 |
| Distance in the 6 min walk test, m | 6.30                 | 0.99 (0.993–0.999) | 0.01 |
| VO2 max (estimated)            | 6.28                   | 0.77 (0.635–0.946) | 0.01 |
| **Echocardiogram data**        |                        |   |   |
| Left ventricular internal dimensions in diastole, mm | 1.57             | 1.03 (0.98–1.09) | 0.21 |
| Left ventricular internal dimensions in systole, mm | 2.33               | 1.02 (0.99–1.04) | 0.13 |
| Septal wall dimension, mm      | 1.44                   | 0.82 (0.597–1.131) | 0.22 |
| Posterior wall dimension, mm   | 0.14                   | 1.02 (0.922–1.128) | 0.70 |
| Relative wall thickness        | 2.4372                 | 0.002 (0.0–5.113)  | 0.12 |
| Left ventricular ejection fraction, % | 3.04             | 0.96 (0.931–1.004) | 0.08 |
| Left ventricular ejection fraction > 45% | 2.18             | 0.329 (0.075–1.44) | 0.14 |
| **Medications**                |                        |   |   |
| Aspirin                        | 0.47                   | 1.55 (0.444–5.433) | 0.49 |
| Anti-coagulation               | 0.17                   | 1.22 (0.474–3.185) | 0.67 |
| Digoxin                        | 0.002                  | 1.02 (0.389–2.677) | 0.96 |
| Oral anti diabetic             | 0.008                  | 1.05 (0.304–3.686) | 0.92 |
| Clopidogrel                    | 0.06                   | 0.81 (0.182–3.679) | 0.79 |
| Insulin                        | 0.98                   | 1.87 (0.539–6.542) | 0.32 |
| Beta-blocker                   | 0.97                   | 0.46 (0.104–2.109) | 0.32 |
| Angiotensin-converting enzyme inhibitor | 0.52             | 1.41 (0.554–3.629) | 0.46 |
| Angiotensin receptor blocker   | 1.04                   | 0.57 (0.203–1.65)  | 0.30 |
| **12-lead resting ECG data**   |                        |   |   |
| Atrial fibrillation            | 0.15                   | 1.36 (0.28–6.5)   | 0.7 |
| Left bundle branch block       | 1.45                   | 2.23 (0.604–8.28) | 0.22 |
| Right bundle branch block      | 3.05                   | 6.39 (0.797–51.293) | 0.08 |
| Left ventricular hypertrophy   | 2.91                   | 0.32 (0.088–1.811) | 0.08 |
| Leaf atrium enlargement        | 0.53                   | 0.61 (0.167–2.271) | 0.46 |
| T inversion                    | 0.02                   | 0.90 (0.271–3.043) | 0.87 |

(Continues)
to other HF real-world cohorts, which showed that high-normal serum potassium levels were safe and presented an equivalent clinical outcome to normal potassium levels.\textsuperscript{21,22}

While there are sufficient data that lower than normal potassium levels should be avoided in HF, there is no consensus on the targeted potassium levels or the upper-safety level.\textsuperscript{21}

The current study data showed that potassium levels below 4.7 mmol/L are associated with improved clinical outcomes compared with higher-normal potassium levels (above 4.7 mmol/L). When added to the lower than average MAGGIC score, the potassium below 4.7 mmol/L group identified the lowest-risk group. Also, potassium levels presented a significant and independent association with cardiac events even in patients with MAGGIC score above the cohort average. Similar to our finding, a recent cohort has concluded that the probable safest potassium interval was narrowed into 4.1–4.8 mmol/L,\textsuperscript{23} not too low or too high potassium levels.

Table 3 (continued)

| ST deviation, ms | LR $\chi^2$ test | HR (95% CI) | P-value |
|------------------|-------------------|-------------|---------|
| QRS duration, ms | 2.33              | 1.01 (0.997–1.026) | 0.005   |
| PR duration, ms  | 0.20              | 1.00 (0.991–1.015) | 0.64    |
| Corrected QT interval, ms | 7.74 | 1.00 (1.003–1.015) | 0.005   |

6MWT, 6 min walking test; CABG, coronary artery bypass graft; CI, confidence interval; ECG, electrocardiogram; Hb1Ac, haemoglobin A1c; HR, hazard ratio; LR, likelihood ratio; MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure; NYHA, New York Heart Association.

Figure 2 The Kaplan–Meier analysis stratified by potassium levels (A), Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score (B), and both potassium levels and MAGGIC score (C).
**Figure 3** The annual event rates of adverse outcomes in relation to Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score and potassium levels. MACE, major cardiovascular events.

![Graph showing annual event rates of adverse outcomes](image)

**Table 4** Multivariable analysis

| Variable                        | LR χ² test | HR (95% CI)       | P-value |
|---------------------------------|-----------|-------------------|---------|
| Potassium                       | 6.1373    | 3.577 (1.305–9.807) | 0.0132  |
| MAGGIC score                    | 3.5260    | 1.093 (0.996–1.200) | 0.0890  |
| Left ventricular ejection fraction | 0.4250    | 0.985 (0.941–1.031) | 0.5144  |
| Age                             | 1.8357    | 0.971 (0.931–1.013) | 0.1755  |

CI, confidence interval; HR, hazard ratio; MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure.

Hazard ratio for outcome prediction including potassium levels, MAGGIC score, left ventricular ejection fraction, and age.

**Table 5** Multivariable analysis for categorical variables

| Variable                        | HR (95% CI)       | P-value |
|---------------------------------|-------------------|---------|
| 6MWT distance (above 300 m)     | 0.9956 (0.9918–0.9995) | 0.029   |
| MAGGIC score                    | 1.68 (0.5431–5.2216) | 0.367   |
| Potassium levels (above 4.7 mmol/L) | 4.109 (1.4707–11.4849) | 0.007   |

6MWT, 6 min walking test; CI, confidence interval; HR, hazard ratio; MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure.

**Table 6** Incremental value of serum K in predicting cardiovascular events (cardiac death, heart failure hospitalization, and heart transplantation) beyond 6 min walking test and Meta-Analysis Global Group in Chronic Heart Failure score

| Variable                        | C-statistic<sup>a</sup> (SE) | P-value<sup>b</sup> | IDI (95% CI)       | P-value<sup>b</sup> | NRI (95% CI)       | P-value<sup>b</sup> |
|---------------------------------|-------------------------------|---------------------|-------------------|---------------------|-------------------|---------------------|
| Model without K: 6MWT + MAGGIC score | 0.649 (0.086) | <0.001   | —                 | —                   | —                 | —                   |
| Model with K: 6MWT + MAGGIC score + K | 0.75 (0.068) | <0.001   | 0.105 (0.018–0.281) | 0.012 | 0.447 (0.077–0.703) | 0.028               |

6MWT, 6 min walking test; CI, confidence interval; IDI, integrated discrimination index; MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure; NRI, net reclassification index; SE, standard error.

<sup>a</sup>C-statistic values were calculated considering the whole follow-up period for the composite outcome, while continuous NRI and IDI were estimated at 2 years.

<sup>b</sup>P values compared with the model containing solely clinical variables.
Additionally, our findings were not correlated with less RAAS inhibitors utilization, because there were no statistical differences on the prescribed medications between patients according to the potassium levels group (lower or higher than 4.7 mmol/L). Furthermore, these findings might bring concern for the HF outpatient treatment optimization regarding potassium, because our data suggest a possible novel threshold for potassium tolerance, independently of the MAGGIC score or 6MWT distance.

Thus, the results of the present observational, prospective study suggest that not only hyperkalaemia or hypokalaemia but also serum potassium levels above 4.7 mmol/L might be associated to adverse cardiovascular outcomes. Our results demonstrated an independent prognostic value of the potassium levels, which was additive to MAGGIC score and 6MWT distance. Whether the potassium levels were directly related to prognosis or had other confounding variables not studied in this present cohort, such as the HF severity, it demands further investigation.

Conclusions

The study found that serum potassium levels are independently associated to worse outcomes in ambulatory patients with chronic symptomatic HF and improved the accuracy model for prognostic prediction when added to MAGGIC score and 6MWT distance. The potassium levels above 4.7 mmol/L might identify those patients at an increased risk of cardiovascular events.

Conflict of interest

C.C.T., P.V.S., L.M.S., G.S.F., F.B.C., V.C.R., L.R.P., L.M.A.C., A. C.S., J.R.M.S., R.M., W.N., L.S.F.C., and O.R.C.-F. declare no conflict of interest.

Funding

Dr Coelho-Filho is supported by grant in research productivity (303366/2015-0) from the National Council for Scientific and Technological Development (CNPq) and by grants from the São Paulo Research Foundation (2015/15402-2, 2016/26209-1, and 2017/03708-5).

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1: Multivariable analysis for outcome prediction including potassium levels, and GFR.

Table S2: Multivariable analysis for outcome prediction including potassium and creatinine level.

References

1. Rohde LEP, Montera MW, Bocchi EA, Clausell NO, Albuquerque DC, Rassi S, Colafranceschi AS, Freitas Junior AF, Ferraz AS, Biolo A, Barretto AC. Diretriz brasileira de insuficiência cardíaca crônica e aguda. Arq Bras Cardiol 2018; 111: 436–539.

2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola V-P, Jankowska EA. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129–2200.

3. Bocchi EA, Braga FGM, Ferreira SMA, Rohde LEP, Oliveira WA, Almeida DR, Moreira MD, Bestetti RB, Bordignon S, Azevedo C, Tínoco EM. III Diretriz brasileira de insuficiência cardíaca crônica. Arq Bras Cardiol 2009; 93: 3–70.

4. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163–2196.

5. Llubani R, Vukadinović D, Werner C, Marx N, Zewinger S, Böhm M. Hyperkalaemia in heart failure—pathophysiology, implications and therapeutic perspectives. Curr Heart Fail Rep 2018; 15: 390–397.

6. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A,
Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543–551.

7. Foley RN, Wang C, Ishani A, Collins AJ. NHANES III: influence of race on GFR thresholds and detection of metabolic abnormalities. J Am Soc Nephrol 2007; 18: 2575–2582.

8. Desai AS. Hyperkalemia in patients with heart failure: incidence, prevalence, and management. Curr Heart Fail Rep 2009; 6: 272–280.

9. Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, Pitt B, Solomon SD. Randomized Aldactone Evaluation Study. Incidence, predictors, and outcomes related to hypokalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 2014; 7: 573–579.

10. Bielecka-Dabrowa A, Mikhailidis DP, Jones L, Rysz J, Aronow WS, Banach M. The meaning of hypokalemia in heart failure. Int J Cardiol 2012; 158: 12–17.

11. Krogager ML, Eggers-Kaas L, Aasbjerg K, Mortensen RN, Kober L, Gislason G, Torp-Pedersen C, Sogaard P. Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction. Eur Heart J Cardiovasc Pharmacother 2015; 1: 245–251.

12. Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, Banerjee S. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol 2012; 109: 1510–1513.

13. Comite Coordenador da Diretriz de Insuficiência C, Rohde LEP, Montero MW, Bocchi EA, Clausell NO, Albuquerque DC, Rassi S, Colafranceschi AS, Freitas AFJ, Ferraz AS, Biolo A, Barretto ACP, Ribeiro ALP, Polanczyk CA, Guandalino DM, Almeida DR, Silva ERR, Figueiredo EL, Mesquita ET, Marcondes-Braga FG, Cruz FDD, Ramires EJA, Atik FA, Bacal E, Souza GEC, de Almeida GLG Jr, Ribeiro GCA, Villacorta HJ, Vieira JL, Souza JDN, Rossi JMN, Figueiredo JAN, Moura LAZ, Goldraich LA, Beck-da-Silva L, Danzmann LC, Canesin MF, Bittencourt MI, Garcia MI, Bonatto MG, Simoes MV, Moreira MCV, Silva MMF, Olivera MTJ, Silvestre OM, Schwartzmann PV, Bestetti RB, Rocha RM, Simoes R, Pereira SB, Mangini S, Alves SMM, Ferreira SMA, Issa VS, Barzilai VS, Martins WA. Diretriz brasileira de insuficiência cardíaca crônica e aguda. Arq Bras Cardiol 2018; 111: 436–539.

14. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Group ESCG. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129–2200.

15. Coelho-Filho OR, Seabra LF, Mongeon R, Di Carli MF, Jerosch-Herold M, Bueno H, Cleland JGF, Coats AJS, Kaski JC, Bakris G, Aban I, Love TE, Aronow WS, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Group ESCG. Stress myocardial perfusion imaging by CMR provides strong prognostic value to cardiac events regardless of patient’s sex. J Am Coll Cardiol Img 2011; 4: 850–861.

16. Lang RM, Badano LP, Mor-Avi V, Afifalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rusdi L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28: 1–39 e14.

17. Hamm LF, Wenger NK, Arena R, Forman DE, Lavie CJ, Miller TD, Thomas RJ. Cardiac rehabilitation and cardiovascular disability: role in assessment and improving functional capacity: a position statement from the American Association of Cardiovascular and Pulmonary Rehabilitation. J Cardiopulm Rehabil Prev 2013-Feb; 33: 1–11.

18. Pocock SJ, Artin CA, McMurray JJ, Maggioni A, Kober L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN, Meta-Analysis Global Group in Chronic Heart F. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 2013; 34: 1404–1413.

19. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157–172 discussion 207-112.

20. Nadruz W Jr, West E, Sengelov M, Santos M, Groarke JD, Forman DE, Claggett B, Skali H, Shah AM. Prognostic value of cardiopulmonary exercise testing in heart failure with reduced, midrange, and preserved ejection fraction. J Am Heart Assoc 2017; 6: e006000.

21. Hoss S, Elizur Y, Luria D, Keren A, Lotan C, Gotsman I. Serum potassium levels and outcome in patients with chronic heart failure. Am J Cardiol 2016; 118: 1866–1874.

22. Ahmed MI, Ekundayo OJ, Mujib M, Campbell RC, Sanders PW, Pitt B, Perry GJ, Bakris G, Aban I, Love TE, Aronow WS, Ahmed A. Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. Int J Cardiol 2010; 144: 383–388.

23. Aldahl M, Jensen AC, Davidsen I, Erikson MA, Moller Hansen S, Nielsen BJ, Krogager ML, Kober L, Torp-Pedersen C, Sogaard P. Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J 2017; 38: 2890–2896.